Clinical trials met healthcare data: how Quintiles and IMS Health became IQVIA
IQVIA combines two older corporate histories: IMS Health, established in 1954 around healthcare information, and Quintiles, founded in 1982 as a clinical research organisation.
The two businesses approached life sciences from different directions, one through data and commercial analytics and the other through drug-development and clinical-trial services.
IQVIA’s present-day business makes more sense when viewed through those early choices. The company repeatedly reused existing expertise rather than reinventing itself from nothing.
Quintiles scaled outsourced clinical development globally
Quintiles expanded clinical trial management, laboratories and development services as pharmaceutical companies increasingly outsourced parts of research operations.
This was an important turning point because it expanded what IQVIA could offer or the markets it could address. The effect becomes clearer when viewed as part of the longer sequence of changes that followed.
IMS Health built a global healthcare-data franchise
IMS collected and analysed pharmaceutical sales and healthcare information used by drug makers for commercial planning and market analysis.
This was an important turning point because it expanded what IQVIA could offer or the markets it could address. The effect becomes clearer when viewed as part of the longer sequence of changes that followed.
The 2016 merger created QuintilesIMS
Quintiles and IMS Health completed a merger of equals in October 2016, combining clinical-development services with data, technology and commercial analytics.
The transaction mattered because it changed the shape of IQVIA rather than simply adding revenue. It brought additional technology, customers, geographic reach or operating capability into the group and influenced the next stage of its strategy.
The 2017 IQVIA name signalled a new integrated model
QuintilesIMS adopted the IQVIA name in November 2017 and increasingly positioned its technology around real-world evidence, analytics and data-enabled clinical research.
This was an important turning point because it expanded what IQVIA could offer or the markets it could address. The effect becomes clearer when viewed as part of the longer sequence of changes that followed.
Two healthcare infrastructures became one data-and-research platform
As of 18 September 2026, iQVIA now operates at the intersection of healthcare data, technology and clinical development. Its history matters because the modern company was deliberately created by combining two complementary forms of life-sciences infrastructure.
The company’s current position is therefore the result of accumulated technical and commercial choices rather than one breakthrough product. That is the context future coverage should preserve.
For TechnologyBlog.co.za, this page is intended to serve as the company-history cornerstone for future IQVIA coverage, so product and company-news articles can link back to one factual brand background instead of repeating the full origin story.
Primary sources checked include IQVIA’s official history and 2016 merger announcement. Information reflects public material available on 18 September 2026. Official company identity cross-checked against http://www.iqvia.com.
